Skip to content
    INFU
    Earnings call· Jun 2026(Q2 FY26)

    InfuSystem Holdings Q2 FY26 earnings call INFU

    Aug 4, 2026 Source

    Executive summary

    InfuSystem Q2 FY26 — Record Revenue and Strong Profitability Growth

    InfuSystem delivered a record revenue quarter, driven by robust growth in its core Oncology business and accelerating expansion in Wound Care, despite the impact of a GE Healthcare contract restructuring. The company achieved significant adjusted EBITDA growth and margin expansion, supported by operational efficiencies and strategic partnerships. Management remains focused on leveraging its new ERP system for further process improvements and maintaining its long-term profitability targets.

    Highlights

    5

    • Record quarterly revenue of $36.9 million, up 2.6% GAAP YoY and 7.5% non-GAAP pro forma YoY.

    • Adjusted EBITDA increased 7.6% to $8.6 million, with margin expanding to 23.4%.

    • Oncology revenue surpassed $20 million for the first time, growing 6.4% YoY.

    • Wound Care net revenue grew by $2.1 million or 154% year-over-year, driven by compression devices.

    • Consolidated gross margin expanded to 58%, an improvement of 2.8 percentage points YoY.

    Concerns

    4

    • Device Solutions revenue declined 16.1% due to GE Healthcare contract restructuring and a prior-year rental customer buyout.

    • Patient Services gross margin modestly declined by 2.4 percentage points to 61.8% due to higher Wound Care mix and increased pump maintenance costs.

    • Selling and marketing expenses increased 10.5% to $3 million, reflecting additional sales resources and higher travel costs.

    • G&A expense increased 7.2% to $14.1 million, driven by higher stock-based compensation, wage inflation, and healthcare costs.

    Guidance & targets

    2
    CategoryTargetConfidence
    Annual Revenue Growth
    6% to 8%
    high materiality
    High
    Adjusted EBITDA Margin
    low to mid-20% range (22% to 25%)
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Patient Services
    Revenue growth driven by Oncology and Wound Care. Gross margin declined due to a larger mix of lower-margin Wound Care revenue and increased pump maintenance costs.
    Gross margin: 61.8%Gross margin YoY change: -2.4 percentage points
    		$24.8 million15.2%—$15.3 million gross profit
    Oncology
    Surpassed $20 million for the first time, driven by higher treatment volumes and improved reimbursement collections. Serves 18 of the top 20 U.S. hospital systems.
    Revenue increase: $1.2 million
    		>$20 million6.4%——
    Wound Care
    Significant growth driven by Pneumatic Compression Devices (PCDs) and Adjustable Compression Wraps, supported by partnerships with two manufacturers.
    Revenue increase: $2.1 millionGrowth driver: Compression devices (nearly 90% of increase)
    		—154%——
    Device Solutions
    Revenue decline primarily due to planned reduction in biomedical services revenue from GE Healthcare contract restructuring and a prior-year rental customer buyout. Gross profit remained stable, and gross margin significantly improved due to restructuring and procurement initiatives.
    Gross margin: 50.2%Gross margin YoY change: +8.3 percentage pointsGE contract restructuring impact on margin: +4.8 percentage points
    		$12.1 million-16.1%—$6.1 million gross profit

    Operational metrics

    14
    Consolidated Gross Profit
    $21.4 million+7.7% YoY
    Q2 FY26
    Consolidated Gross Margin
    58%+2.8 percentage points YoY
    Q2 FY26
    Net Income
    $3.2 millionvs $2.6 million prior year
    Q2 FY26
    Diluted EPS
    $0.15vs $0.12 prior year
    Q2 FY26
    Investment in Rental Equipment
    $6.5 million
    H1 FY26

    To support growth.

    Share Repurchases
    $4.4 million
    H1 FY26
    Available Liquidity
    $55.2 million
    Q2 FY26
    Net Debt
    $19.5 million
    Q2 FY26
    Selling and Marketing Expenses
    $3 million+10.5% YoY
    Q2 FY26

    Reflecting additional sales resources and higher travel costs.

    G&A Expense
    $14.1 million+7.2% YoY
    Q2 FY26

    Driven by higher stock-based compensation, wage inflation, health care costs, and investments in Patient Services.

    GE Healthcare Contract Restructuring Revenue Impact
    $1.6 millionreduction
    Q2 FY26

    Basis for non-GAAP pro forma revenue adjustment. Allowed for larger reduction in direct contract expenses.

    ERP Spending
    $300,000sequential decrease; vs $600,000-$700,000 prior year
    Q2 FY26

    Focused on post-go-live stabilization and enhancement activities. Expected to continue tapering down.

    Medicare Exposure
    below 10%
    Q2 FY26
    Payer Contracts
    800+
    Q2 FY26

    Industry KPIs

    3
    MetricValueDetails
    Utilization trendshigher treatment volumes
    Segment revenue operating income$24.8 millionUSD
    Adjusted EPS EBITDA leverage guidance$8.6 millionUSD

    Risks & headwinds

    3
    Revenue reduction from GE Healthcare contract restructuringQ2 FY26 and ongoing annually

    $1.6 million in Q2 FY26, $7.1 million annually

    Mitigation: Restructuring improved earnings by allowing for a larger reduction in direct contract expenses.

    Modest decline in Patient Services gross marginQ2 FY26

    -2.4 percentage points to 61.8%

    Mitigation: Attributable to a larger mix of lower-margin Wound Care revenue and increased pump maintenance costs; company sees opportunities to improve profitability of new products.

    Increased operating expensesQ2 FY26

    Selling and marketing up 10.5% to $3 million; G&A up 7.2% to $14.1 million

    Mitigation: Investments in sales resources, Patient Services business, and ERP system are expected to drive future growth and efficiencies.

    What to watch in Q3 FY26

    3

    Wound Care Revenue Growth

    Q3 FY26 and beyond
    Current154% YoY
    TargetContinued strong growth

    Why it matters

    Wound Care, particularly lymphedema compression devices, is a key growth driver for the company, and its sustained performance is critical for overall revenue expansion.

    Yes. We've seen great success growing. We have a couple of new partners there. As we've talked about in the past, I think we're 154% growth. So we continue to see volume coming in. That is improving, and we continue to foresee that happening through the remainder of 2026 and certainly beyond. So yes, I would expect some continued growth there.

    Q&A highlights

    7

    Is the 6% oncology growth sustainable?

    Management believes the 6.4% oncology growth is sustainable due to increasing volumes, new customer additions, and improved collections/reimbursement.

    “I think we've continued to see a little bit higher than that single kind of lower digit growth over the years. We're seeing -- starting to see some great volume. We've added some new customers this year. And then our collections and reimbursement improvements are also contributing to that. So I do think it's pretty sustainable moving forward.”

    asked by James Sidoti · answered by Carrie Lachance

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Revenue Growth Despite Restructuring Impact

    InfuSystem reported record Q2 FY26 revenue of $36.9 million, representing a 2.6% GAAP year-over-year increase. On a non-GAAP pro forma basis, excluding a $1.6 million reduction in biomedical services revenue due to the GE Healthcare contract restructuring, revenue growth was 7.5%. This demonstrates continued strength in core operations, with the GE restructuring improving earnings by allowing for a larger reduction in direct contract expenses.

    02

    Accelerating Growth in Wound Care

    Wound Care net revenue surged by $2.1 million or 154% year-over-year in Q2 FY26, primarily driven by compression devices for lymphedema patients. The company has established partnerships with two manufacturers, offering both Pneumatic Compression Devices (PCDs) and Adjustable Compression Wraps. This new product line, added less than a year ago, is expected to continue driving near-term growth and open opportunities for additional manufacturing relationships.

    03

    Oncology Business Sustains Strong Performance

    The core Oncology business continued its robust performance, with quarterly revenue exceeding $20 million for the first time and growing 6.4% year-over-year. This growth was attributed to higher treatment volumes, improved reimbursement collections, and the addition of new customers. Management believes this growth trajectory is sustainable, further extending InfuSystem's large share of the outpatient oncology ambulatory infusion market.

    04

    ERP System Enhancements Driving Efficiency

    Following a successful launch, InfuSystem made significant progress in stabilizing and enhancing its new ERP system during Q2 FY26, leading to a sequential decrease in spending on the project. The company is focused on leveraging the ERP application to drive improved capacity and efficiencies across various processes, including working capital management, device throughput, and asset utilization. While refinement continues, the ERP is expected to yield long-term operational benefits.

    05

    Financial Flexibility and Capital Allocation

    InfuSystem generated $7.7 million in operating cash flow during the first six months of the year, investing $6.5 million in rental equipment to support growth and returning $4.4 million to shareholders through share repurchases. The company ended the quarter with $55.2 million in available liquidity, including $54.2 million of revolver availability, and maintains a conservative leverage profile with net debt of $19.5 million, representing 0.61x trailing 12-month adjusted EBITDA.

    AI-generated summary of the company’s earnings call. Not investment advice.